Osteoporosis treatment gap and risk of refracture: a pilot retrospective study on a cohort of patients referred to a Fracture Liaison Service in Italy
Frontiers in Musculoskeletal Disorders · 23.06.2025 · 3
DOI: 10.3389/fmscd.2025.1620506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Musculoskeletal Disorders, online erschienen am 23.06.2025. Verfasst von Giammarco De Mattia und 7 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The timely administration of anti-osteoporotic medications (AOM) to patients with fragility fractures (FF) reduces the imminent refracture risk. European studies found a wide osteoporosis treatment gap, but Italian cohort-based data are lacking. Materials and methods We aimed to assess the entity of the osteoporosis treatment gap in an Italian cohort, i.e., the percentage of patients not treated within 2 months from the index fragility fractures (FF) and the time delay in anti-osteoporotic medications (AOM) administration, and its impact on refracture risk. We retrospectively collected the clinical histories of 500 randomly selected osteoporotic patients with FFs referred to our Fracture Liaison Service. We identified those who had AOM prescribed within 2 months from the index FF (“early treatment” group) and those who had not (“untreated” group). Refracture occurrence was retrospectively assessed in both groups, followed by a survival and risk analysis.
Results
Forty-one patients were excluded for missing data. Out of 459 patients, 374 (81.5%) received AOM therapy more than 2 months after the index FF, with a median delay of 24 months (IQR 52) (range 3–312; mean 47 months). The log-rank test showed that the “untreated” group was significantly more prone to refracture than “early treatment” (78% vs. 48%, respectively; p = 0.0001). Cox regression revealed a 44% lower probability of refracture in the “early treatment” group.
Discussion
In this study, 81.5% of individuals had their first AOM prescription after a median time of 24 months after the index FF, resulting in higher refracture risk. Preventive strategies to reduce the osteoporosis treatment gap should be implemented.
Zitieren
APA
Mattia, G. D., Manca, M. L., Bottai, V., Antognetti, D., Menconi, A., Maffi, M., Mosca, M., & Mazzantini, M. (2025). Osteoporosis treatment gap and risk of refracture: a pilot retrospective study on a cohort of patients referred to a Fracture Liaison Service in Italy. Frontiers in Musculoskeletal Disorders, 3. https://doi.org/10.3389/fmscd.2025.1620506
Vancouver
Mattia GD, Manca ML, Bottai V, Antognetti D, Menconi A, Maffi M, et al. Osteoporosis treatment gap and risk of refracture: a pilot retrospective study on a cohort of patients referred to a Fracture Liaison Service in Italy. Frontiers in Musculoskeletal Disorders. 2025;3. doi:10.3389/fmscd.2025.1620506
BibTeX
@article{Mattia2025,
author = {Mattia, Giammarco De and Manca, Maria Laura and Bottai, Vanna and Antognetti, Damiano and Menconi, Agnese and Maffi, Michele and Mosca, Marta and Mazzantini, Maurizio},
title = {Osteoporosis treatment gap and risk of refracture: a pilot retrospective study on a cohort of patients referred to a Fracture Liaison Service in Italy},
journal = {Frontiers in Musculoskeletal Disorders},
year = {2025},
volume = {3},
doi = {10.3389/fmscd.2025.1620506}
}
EUVIMED